The Effects of 12-Week Beta-Hydroxy-Beta-Methylbutyrate Supplementation in Patients with Liver Cirrhosis: Results from a Randomized Controlled Single-Blind Pilot Study.
Anthropometry
Dietary Supplements
Electric Impedance
Exercise
/ physiology
Female
Frailty
/ etiology
Humans
Liver Cirrhosis
/ complications
Male
Middle Aged
Muscle Strength
/ drug effects
Muscle, Skeletal
/ drug effects
Pilot Projects
Sarcopenia
/ etiology
Single-Blind Method
Treatment Outcome
Valerates
/ administration & dosage
beta-hydroxy-beta-methylbutyrate
frailty
liver cirrhosis
sarcopenia
Journal
Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595
Informations de publication
Date de publication:
02 Jul 2021
02 Jul 2021
Historique:
received:
14
05
2021
revised:
28
06
2021
accepted:
28
06
2021
entrez:
10
8
2021
pubmed:
11
8
2021
medline:
10
9
2021
Statut:
epublish
Résumé
Sarcopenia is considered an important risk factor for morbidity and mortality in liver cirrhosis. Beta-hydroxy-beta-methylbutyrate (HMB) has the potential to increase muscle mass and performance by stimulating protein synthesis and reducing muscle catabolism. The present study aimed at evaluating the effect of HMB supplementation on muscle mass and function in patients with liver cirrhosis. Changes in frailty during the study were also estimated, and the safety of HMB supplementation was verified. This is a randomized, single-blind, placebo-controlled pilot trial. Twenty-four patients (14 HMB and 10 placebo) affected by liver cirrhosis were enrolled in the study. Each patient received dedicated counseling, which included nutrition and physical activity recommendations for chronic liver disease patients. Patients were randomized to receive 3 g/day of HMB or placebo (sorbitol powder) for 12 consecutive weeks. A diet interview, anthropometry, electrical bioimpedance analysis (BIA), quadriceps ultrasound, physical performance battery, Liver Frailty Index (LFI), and cognitive tests were completed at enrolment (T0), at 12 weeks (T1), and 24 weeks after enrolment (T2). At baseline, the two groups were similar in demography, severity of liver disease, muscle mass, muscle function, and cognitive tests. LFI at baseline was higher in patients in the HMB group vs. those in the placebo group (4.1 ± 0.4 vs. 3.4 ± 0.6, Our study suggests the efficacy of 12-week beta-hydroxy-beta-methylbutyrate supplementation in promoting improvements in muscle performance in compensated cirrhotic patients. LFI was also ameliorated. Further studies with a greater number of patients are required to reinforce this hypothesis.
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
Sarcopenia is considered an important risk factor for morbidity and mortality in liver cirrhosis. Beta-hydroxy-beta-methylbutyrate (HMB) has the potential to increase muscle mass and performance by stimulating protein synthesis and reducing muscle catabolism. The present study aimed at evaluating the effect of HMB supplementation on muscle mass and function in patients with liver cirrhosis. Changes in frailty during the study were also estimated, and the safety of HMB supplementation was verified.
METHODS
METHODS
This is a randomized, single-blind, placebo-controlled pilot trial. Twenty-four patients (14 HMB and 10 placebo) affected by liver cirrhosis were enrolled in the study. Each patient received dedicated counseling, which included nutrition and physical activity recommendations for chronic liver disease patients. Patients were randomized to receive 3 g/day of HMB or placebo (sorbitol powder) for 12 consecutive weeks. A diet interview, anthropometry, electrical bioimpedance analysis (BIA), quadriceps ultrasound, physical performance battery, Liver Frailty Index (LFI), and cognitive tests were completed at enrolment (T0), at 12 weeks (T1), and 24 weeks after enrolment (T2).
RESULTS
RESULTS
At baseline, the two groups were similar in demography, severity of liver disease, muscle mass, muscle function, and cognitive tests. LFI at baseline was higher in patients in the HMB group vs. those in the placebo group (4.1 ± 0.4 vs. 3.4 ± 0.6,
CONCLUSIONS
CONCLUSIONS
Our study suggests the efficacy of 12-week beta-hydroxy-beta-methylbutyrate supplementation in promoting improvements in muscle performance in compensated cirrhotic patients. LFI was also ameliorated. Further studies with a greater number of patients are required to reinforce this hypothesis.
Identifiants
pubmed: 34371806
pii: nu13072296
doi: 10.3390/nu13072296
pmc: PMC8308449
pii:
doi:
Substances chimiques
Valerates
0
beta-hydroxyisovaleric acid
3F752311CD
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Références
Clin Nutr. 2019 Oct;38(5):2071-2078
pubmed: 30360984
J Cachexia Sarcopenia Muscle. 2016 Mar;7(1):68-78
pubmed: 27065075
Nutr Metab (Lond). 2008 Jan 03;5:1
pubmed: 18173841
Liver Int. 2021 Apr;41(4):799-809
pubmed: 33290614
J Hepatol. 2019 Jan;70(1):172-193
pubmed: 30144956
PLoS One. 2016 Mar 08;11(3):e0150066
pubmed: 26953693
Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15603-7
pubmed: 9861016
Int J Behav Nutr Phys Act. 2011 Oct 21;8:115
pubmed: 22018588
Hepatology. 2017 Jul;66(1):198-208
pubmed: 28271528
FASEB J. 2003 Jan;17(1):59-60
pubmed: 12528713
Ann Hepatol. 2021 Feb 14;25:100327
pubmed: 33596465
Liver Transpl. 2021 Jan;27(1):16-26
pubmed: 32946660
Clin Gastroenterol Hepatol. 2016 Oct;14(10):1473-1480.e3
pubmed: 27189915
Clin Nutr ESPEN. 2021 Apr;42:272-279
pubmed: 33745592
J Nutr Health Aging. 2019;23(2):145-150
pubmed: 30697623
Cancer Res. 2005 Jan 1;65(1):277-83
pubmed: 15665304
Growth Horm IGF Res. 2011 Apr;21(2):57-62
pubmed: 21237681
Hepatology. 2019 Nov;70(5):1704-1713
pubmed: 31038758
BMC Gastroenterol. 2020 Nov 9;20(1):371
pubmed: 33167879
Metab Brain Dis. 2013 Jun;28(2):281-4
pubmed: 23224378
PLoS One. 2016 Mar 24;11(3):e0151652
pubmed: 27011355
J Hepatol. 2020 Sep;73(3):575-581
pubmed: 32240717
J Cachexia Sarcopenia Muscle. 2017 Aug;8(4):529-541
pubmed: 28493406
JAMA Surg. 2021 Mar 1;156(3):256-262
pubmed: 33377947
Dig Liver Dis. 2019 Nov;51(11):1508-1512
pubmed: 31601536
Exp Gerontol. 2013 Nov;48(11):1303-10
pubmed: 23981904
J Hepatol. 2001 May;34(5):768-73
pubmed: 11434627
Farm Hosp. 2017 Jul 01;41(4):543-549
pubmed: 28683706
Hepatology. 2017 Aug;66(2):564-574
pubmed: 28422306
Clin Transl Gastroenterol. 2015 Jul 16;6:e102
pubmed: 26181291
Nutrients. 2019 Sep 19;11(9):
pubmed: 31546969
Nutrients. 2019 Sep 03;11(9):
pubmed: 31484462
Liver Int. 2018 May;38(5):851-857
pubmed: 29323441
Biochim Biophys Acta. 2009 May;1793(5):755-63
pubmed: 19211028
J Hepatol. 2016 Dec;65(6):1232-1244
pubmed: 27515775
Biochem Biophys Res Commun. 2012 Jul 13;423(4):739-43
pubmed: 22705301
J Gastroenterol Hepatol. 2021 Feb 27;:
pubmed: 33638197